Our first product was approved and made available to NHS hospitals in May 2019, our second product was made available to NHS and private hospitals in March 2020. Our portfolio will increase in 2021.
We are proud to have an exceptional partner in Phebra Pty Ltd who have their own modern MHRA and FDA approved specialist injectable medicines manufacturing facility which has ample capacity to supply UK demand. In addition, because of the mutual recognition agreements in place between the regulatory authorities of the UK and Australia supply of finished product into the UK from Australia, is straightforward and fast.
Indicated for the treatment of low-intermediate risk acute promyelocytic leukaemia, this is a novel presentation of arsenic trioxide. The Summary of Product Characteristics can be found at https://www.medicines.org.uk/ emc/product/10278/smpc
Arsenic Trioxide Phebra is a generic product which offers several advantages to the NHS;
Further information can be found at www.arsenictrioxidephebra.com
Indicated primarily in the treatment of medicinal and chemical induced and genetic methaemoglobinaemia that are not due to a structural abnormality ofhaemoglobin. Methylthiononinium Chloride is indicated in adults, adolescentsand children (0-17 years old.) The summary of product characteristics can be found at https://www.medicines.org.uk/emc/product/11181
Flexipharm Austrading’s Methylthioninium Chloride 10mg/ml Sterile concentrate for solution for injection is the first and only generic licensed medicinal product presentation of methylthioninium chloride to be available in a preferred vial presentation. As an MHRA licensed and European Pharmacopoeia compliant product, it meets or exceeds specifications on levels of organic and metal impurities, and has several benefits to the NHS, notably:
1. https://bnf.nice.org.uk/medicinal-forms/methylthioninium-chloride.html, ampoules, £196.89 per pack, accessed 04/03/2020. NHS/List price Methylthioninium Chloride vials £150.00 per pack